5 Metabolic Markers Every Practitioner Should Track Before a Client Starts a GLP-1

By Michael Rutherford · Wholistic Health Academy

GLP-1 receptor agonists have become the most talked-about pharmaceutical intervention in metabolic health. But the conversation around these medications is almost entirely focused on outcomes — weight loss, HbA1c reduction, cardiovascular event reduction. What's missing from that conversation is the baseline. Without a comprehensive metabolic baseline established before medication begins, practitioners lose the ability to distinguish genuine metabolic recovery from pharmaceutical masking — and they lose the clinical leverage to determine whether the medication was even the right starting point.

This matters whether you prescribe, co-manage alongside a prescriber, or work exclusively with lifestyle and nutritional interventions. The metabolic picture your client presents with before any pharmaceutical intervention tells you what's actually driving the dysfunction — and that picture requires more than fasting glucose and an HbA1c.

What follows are the five markers that establish a functional metabolic baseline. They represent Tier 1 of the clinical decision tree — the foundational layer where blood sugar and insulin dynamics either support or undermine every other system in the body.

1. Fasting Insulin — The Earliest Marker to Shift

If you could only add one marker to every client's metabolic panel, this would be it. Fasting insulin is the earliest indicator of insulin resistance — it begins climbing years, often a decade or more, before fasting glucose crosses the conventional threshold of 100 mg/dL.¹

The physiology is straightforward. As tissues become less responsive to insulin, the pancreas compensates by producing more of it. Glucose stays normal because the pancreatic beta cells are working harder to maintain homeostasis. This compensatory hyperinsulinemia is the first measurable sign that the metabolic foundation is shifting — and it's completely invisible on a standard metabolic panel.

Conventional lab ranges for fasting insulin extend up to 24.9 μIU/mL. A client with a fasting insulin of 14 will be told everything is "normal." But functionally, that value represents a pancreas under significant strain and a system already moving along the insulin resistance continuum.

This is where the GLP-1 conversation gets clinically interesting. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner — they enhance insulin's effectiveness rather than simply forcing more production. But without knowing where fasting insulin started, you cannot evaluate whether the medication is reducing compensatory hyperinsulinemia (a genuine improvement) or simply modifying the metabolic numbers without addressing the upstream insulin resistance driving the compensation.

2. HOMA-IR — Quantifying Where They Sit on the Continuum

HOMA-IR — calculated as (Fasting Insulin × Fasting Glucose) / 405 — converts two individual markers into a single index that quantifies insulin resistance with more clinical utility than either marker alone.²

The power of HOMA-IR lies in its ability to capture the relationship between glucose and insulin. A fasting glucose of 92 mg/dL with a fasting insulin of 4 μIU/mL tells a fundamentally different story than a fasting glucose of 92 mg/dL with a fasting insulin of 16 μIU/mL. The glucose is identical. The metabolic reality is not.

In the context of GLP-1 decision-making, HOMA-IR provides the clearest picture of where your client sits on the insulin resistance progression. Research has established optimal HOMA-IR cut-offs that distinguish between healthy insulin sensitivity, developing resistance, and established dysfunction.³ A client with a HOMA-IR below 1.5 is in a metabolic position where foundational interventions — dietary modification, movement protocols, sleep optimization, stress management — may be sufficient. A client above 3.0 may genuinely benefit from pharmaceutical support alongside those foundations. Without HOMA-IR, you're guessing.

3. HbA1c — Beyond the Conventional Threshold

HbA1c is perhaps the most recognized metabolic marker — and the one most frequently used to justify GLP-1 prescriptions. It reflects average blood glucose over the previous 90 days by measuring the percentage of hemoglobin molecules that have glucose attached. This three-month window makes it a more stable indicator than single-point fasting glucose measurements.

The problem lies in the conventional interpretation. A value of 5.6% is considered normal, and 5.7% marks the beginning of "prediabetes." But research demonstrates that cardiovascular risk begins climbing at HbA1c values well within the conventional normal range — values as low as 5.4–5.5% are associated with increased cardiometabolic disease risk in nondiabetic populations.⁴

Equally important is the low end of the range. Research has demonstrated a U-shaped mortality curve, with HbA1c values below 5.0% associated with increased all-cause mortality in nondiabetic adults.⁵ This means that an HbA1c that's too low — often seen in reactive hypoglycemia patterns or caloric restriction — also carries clinical significance. The functional optimal window of 4.8–5.4% reflects both sides of this curve.

For GLP-1 monitoring, HbA1c is the marker that will be tracked most closely by the prescribing provider. Having your own baseline using functional ranges — not just the conventional threshold — gives you the clinical context to evaluate whether the medication's effect represents genuine metabolic improvement or a pharmacological shift in numbers that doesn't reflect upstream change.

4. Triglyceride/HDL Ratio — The Lipid Panel's Hidden Metabolic Signal

Most practitioners evaluate triglycerides and HDL as individual cardiovascular markers. But the ratio between them is one of the strongest surrogate markers for insulin resistance available on a standard lipid panel — and often more revealing than either value in isolation.⁶

The physiology behind this ratio connects directly to insulin resistance. When cells become resistant to insulin, excess glucose gets converted to triglycerides through de novo lipogenesis in the liver. Simultaneously, HDL metabolism shifts — clearance increases and production may decrease. The result is the metabolic dyslipidemia pattern: triglycerides climb while HDL drops. Elevated triglycerides are associated with insulin resistance in roughly 99% of cases, and the TG/HDL ratio captures this relationship in a single calculated value.⁷

A TG/HDL ratio below 2.0 suggests healthy insulin sensitivity. A ratio above 3.5 strongly suggests insulin resistance, even when individual lipid values fall within conventional ranges. This pattern — high triglycerides with low HDL and often small, dense LDL particles — is the metabolic signature of insulin resistance, and it frequently appears before glucose markers shift.

GLP-1 medications improve lipid profiles. This is well documented. But lipid improvement driven by the medication is mechanistically different from lipid improvement driven by restored insulin sensitivity through foundational interventions. The pre-medication TG/HDL ratio gives you the reference point to distinguish between the two.

5. GGT — The Metabolic Liver Marker That Belongs on Every Panel

Gamma-glutamyl transferase is the most sensitive marker for early liver dysfunction and oxidative stress — yet it's not included on a standard comprehensive metabolic panel. This is a significant gap, because the liver is the metabolic hub where glucose, lipid, and hormone metabolism converge.

GGT elevations often appear before ALT or AST become abnormal, making it an early warning system for the kind of metabolic liver stress that frequently accompanies insulin resistance.⁸ A normal ALT with an elevated GGT indicates systemic oxidative stress without overt liver cell damage — a pattern that standard liver panels miss entirely.

This is particularly relevant in the GLP-1 context for two reasons. First, metabolic dysfunction–associated steatotic liver disease (MASLD) — formerly known as NAFLD — affects a significant portion of people with insulin resistance, and GGT is one of the earliest markers to flag this progression. Second, GLP-1 medications can affect liver enzyme levels, and without a pre-medication GGT baseline, any subsequent changes become uninterpretable — you can't distinguish between medication effects and underlying metabolic liver stress that was already present.

Why These Five Markers Change the Conversation

The metabolic health conversation has shifted dramatically toward pharmaceutical solutions. GLP-1 medications are powerful tools — but they're tools that work best when the clinical picture is clear. These five markers provide that clarity.

Together, they tell you whether your client has early-stage insulin resistance that responds to foundational interventions, established metabolic dysfunction that may benefit from pharmaceutical support alongside lifestyle changes, or metabolic liver stress that needs to be addressed regardless of the therapeutic path chosen. They establish the baseline that transforms medication monitoring from "is the number going down?" to "is the underlying metabolic dysfunction actually improving?" This is the essence of pattern recognition in blood chemistry — reading the story the markers tell together, not evaluating them in isolation.

Stabilizing blood sugar is the single most effective way to lower systemic inflammation and balance hormones. These five markers are the instruments that measure whether that stabilization is happening — whether through lifestyle interventions, pharmaceutical support, or both.

Frequently Asked Questions

What is the best blood test to check before starting a GLP-1 medication?

There is no single best test — the metabolic picture requires at least five markers: fasting insulin, HOMA-IR, HbA1c, TG/HDL ratio, and GGT. Together, these establish the metabolic baseline needed to evaluate whether a GLP-1 medication is addressing the root dysfunction or masking the numbers.

Can functional practitioners order these labs for clients?

Lab ordering authority varies by credential and jurisdiction. Many functional practitioners work with direct-access lab services or co-manage with providers who can order these markers. The critical step is ensuring these five markers are included in whatever panel is ordered — not relying on the standard metabolic panel alone.

Why is fasting insulin not included on standard lab panels?

Standard metabolic panels were designed for disease detection, not early dysfunction identification. Fasting insulin becomes clinically abnormal by conventional standards only at very advanced stages of metabolic dysfunction. The functional approach recognizes that the gap between optimal insulin sensitivity and conventional insulin "abnormality" spans years of progressive dysfunction — years where intervention has the most impact.

How often should these markers be rechecked after a client starts a GLP-1?

Most practitioners recheck metabolic baselines at 90-day intervals, which aligns with the HbA1c measurement window. This cadence allows enough time for metabolic changes to manifest while providing regular checkpoints to evaluate progress and adjust the intervention strategy.

Is HOMA-IR more useful than fasting glucose alone?

Significantly. Fasting glucose is one of the last metabolic markers to become abnormal in the insulin resistance progression. A client can have a perfectly normal fasting glucose of 88 mg/dL while their HOMA-IR reveals established insulin resistance. The calculated index captures the relationship between glucose and insulin production — a dimension that glucose alone cannot provide.

Written by Michael Rutherford · Wholistic Health Academy